Figure 2
From: BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma
Glioma stem cell phenotype is modulated by treatment with BMP4 or TGF-β1. (A) Relative BrdU incorporation in G144, G179, and BT046 cells, treated with BMP4 or BMP and LY364947, compared to control (n = 3, *p < 0.01). (B) Relative BrdU incorporation in G144, G179, and BT046 cells, treated with TGF-β1 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.05). (C) Western blot analysis for the stem cell markers ID1, Bmi1, Sox2, and nestin, following treatment of BT046 with BMP4, LY364947, TGF-β1, or noggin. (D) Western blot analysis for POU3F2, Sall2, Sox2, and Olig2, in BT046 cells following treatment with BMP4, LY364947, TGF-β1, or noggin. (E) Sphere formation by BT046 following treatment with BMP4 and LY364947 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.05). (F) Average diameter of spheres formed by BT046 following treatment with BMP4 and LY364947 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.01). (G) Serial passaging of G144, G179, and BT046 cells treated with BMP4 (n = 3, N.S.).
